GlassScriptPhysician profile
Ashley Miller
NPI 1750772893
$412.36
in general payments reported to CMS, 2019-2025
12 companies · $51.52 in 2025
The $51.52 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $46.10 · 2022: $35.38 · 2023: $92.87 · 2024: $186 · 2025: $51.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $330.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $116.48 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
| Merck Sharp & Dohme LLC | $90.16 | 2021-2024 | Vaxneuvance, Gardasil 9, Gardasil |
| Astellas Pharma US INC | $43.61 | 2024 | Veozah |
| Glaxosmithkline, LLC. | $26.93 | 2024-2025 | Bexsero, Pediarix |
| Bioventus LLC | $19.82 | 2024 | Gelsyn-3 |
| Novartis Pharmaceuticals Corporation | $18.99 | 2024 | |
| Abbvie INC. | $18.86 | 2023 | |
| Sanofi Pasteur INC. | $17.32 | 2021 | |
| Alk-Abello, INC | $16.50 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $15.81 | 2023 | |
| Pfizer INC. | $14.26 | 2022 | |
| Forte Bio-Pharma LLC | $13.62 | 2023 | Prolate, Nalocet |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.